Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: Results of a retrospective evaluation

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 4, 2009, Pages 486-490

  Zopf, Steffen ^a   Herold, Christoph ^a   Hahn, Eckhart G ^a   Ganslmayer, Marion ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hepatitis C; Peginterferon; Ribavirin; Weight based dosage

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; COHORT ANALYSIS; DRUG COMBINATION; GENETICS; HEPATITIS C VIRUS; MIDDLE AGED; RECURRENT DISEASE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BODY WEIGHT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 67049137967     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802647400     Document Type: Article

References (22)

1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-82.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-53.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
7. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-81.
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426-32.
10. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008;13 Suppl 1:3-8.
11. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007;14 Suppl 1:82-8.
12. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-9.
13. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123: 1061-9.
14. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
15. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Had-ziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9.
16. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007;46: 1688-94.
17. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
18. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
19. Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007;46:982-90.
20. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9.
21. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93.
22. Schering-Plough. Schering-Plough reports top-line results of the IDEAL Study. 2008.